Showing results (21-30 of 98) with videos related to
Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|July 24, 2014
A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopeniaMartha L Arellano, Gautam Borthakur, Mark Berger, et al.Leukemia Research|May 18, 2007
Clustering in the incidence of myelodysplastic syndromesXiaomei Ma, Steve Selvin, Azra Raza, et al.Cancer|August 23, 2008
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemiaAzra Raza, Murtaza Mehdi, Muhammad Mumtaz, et al.Journal of Hematology & Oncology|April 27, 2010
Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposureFahd Quddus, Jessica Clima, Helen Seedham, et al.Leukemia Research|November 25, 2016
Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)Antonio Almeida, Pierre Fenaux, Alan F List, et al.Proceedings of the National Academy of Sciences of the United States of America|May 30, 2019
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignanciesFlorence Borot, Hui Wang, Yan Ma, et al.Cancer|November 7, 2008
Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalitiesOlga Pozdnyakova, Patricia M Miron, Guilin Tang, et al.Cancer Causes & Control : CCC|February 3, 2011
Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromesXiaomei Ma, Rong Wang, Naomi Galili, et al.Seminars in Hematology|June 11, 2004
Targeted therapies in myelodysplastic syndromes: ASH 2003 reviewAnna Candoni, Federico Silvestri, Silvia Buonamici, et al.Leukemia & Lymphoma|January 7, 2006
Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromesAzra Raza, Laurie Lisak, Jennifer Billmeier, et al.Pageof 10